Article
Dallas-Essilor Laboratories of America has completed the required testing and is ready to provide eyewear that complies with the American National Standards Institute's new Z87.1-2003 standard when it takes effect Aug. 19.
Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Importance of evaluating cerebrospinal fluid at vitreoretinal lymphoma diagnosis
Bausch + Lomb publishes results from phase 4 study evaluating patient-reported outcomes with Miebo in dry eye disease